[1]童强,王慧,管凌志,等.艾塞那肽对2型糖尿病患者的C肽影响及疗效观察[J].陆军军医大学学报(原第三军医大学学报),2014,36(15):1604-1606.
 Tong Qiang,Wang Hui,Guan Lingzhi,et al.Clinical effects of exenatide in treatment of type 2 diabetes and on expression of C-peptide[J].J Amry Med Univ (J Third Mil Med Univ),2014,36(15):1604-1606.
点击复制

艾塞那肽对2型糖尿病患者的C肽影响及疗效观察(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
36卷
期数:
2014年第15期
页码:
1604-1606
栏目:
论著
出版日期:
2014-08-15

文章信息/Info

Title:
Clinical effects of exenatide in treatment of type 2 diabetes and on expression of C-peptide
作者:
童强王慧管凌志王小翠赵渝
重庆医科大学附属第一医院血管外科;第三军医大学新桥医院内分泌科
Author(s):
Tong Qiang Wang Hui Guan LingzhiWang XiaocuiZhao Yu
Departmen of Vascular Surgery, First Affiliated Hospital, Chongqing Medical University, Chongqing, 400042; Department of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
关键词:
GLP-1受体激动剂艾塞那肽2型糖尿病
Keywords:
glucagon-like peptide-1 receptor exenatide type 2 diabetes
分类号:
R587.1; R969.4; R977.15
文献标志码:
A
摘要:
目的      观察艾塞那肽对2型糖尿病患者C肽的影响及临床疗效。      方法        选取2012年1月至2013年6月在新桥医院内分泌科住院的2型糖尿病患者78例,分为治疗组(n=39),给予二甲双胍联合艾塞那肽治疗,包括男性16例,女性23例,年龄(49.0±6.0)岁;对照组(n=39),给予二甲双胍联合甘精胰岛素治疗,包括男性21例,女性18例,年龄(50.1±5.9)岁。两组均治疗16周。监测并分析两组治疗前后空腹及餐后2 h C肽、空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-hour postprandial blood glucose,2hPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、体质量指数(BMI)等相关指标的变化。      结果       治疗16周后治疗组空腹及餐后2 h C肽水平[(2.34±0.51)、(2.66±0.99)ng/mL]均较治疗前[(1.89±0.63)、(1.09±0.46)ng/mL]有所增高(P<0.05),但对照组C肽治疗前后无明显变化(P>0.05);两组患者治疗后的FBG、2hPG、HbA1c[治疗组治疗后分别为(6.94±0.75)、(9.98±0.85)mmol/L,(6.87±0.89)%]均较治疗前[治疗组治疗前分别为(10.06±1.98)、(12.3±0.75)mmol/L,(8.89±1.15)%]有所降低(P<0.05),且两组之间差异无统计学意义(P>0.05);两组患者体质量、腹围及BMI均较治疗前有所下降,治疗组降低更明显(P<0.05)。      结论        艾塞那肽联合二甲双胍在提高2型糖尿病患者的C肽水平的同时能够降低患者的血糖、HbA1c、体质量、腹围及BMI。
Abstract:
Objective       To determine the effects of exenatide on the expression of C-peptide and on the clinical outcome in the treatment of type 2 diabetes.       Methods      A total of 78 hospitalized patients with type 2 diabetes in our department from January 2012 to June 2013 were prospectively recruited, and then divided into 2 groups, the control group and the treatment group. The treatment group had 39 patients, including 16 males and 23 females, at an average age of 49.0±6.0, and received metformin combined with exenatide. Whereas, there were 39 patients in the control group, including 21 males and 18 females, with the average age of 50.1±5.9 and being given metformin combined with Gansulin. All these patients were treated for 16 weeks. The indicates, including fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), fasting C-peptide, 2-hour postprandial C-peptide, and BMI were compared between 2 groups before and after treatment.       Results        At 16 weeks after the treatment, the fasting and 2-h postprandial C-peptide levels were increased in the treatment group (P<0.05), but the control group had no obvious change in the 2 indicators (P>0.05). FBG, 2hPG and HbA1c were significantly decreased in the both 2 groups (P<0.05), but there was no statistical difference between them (P>0.05). The body weight, circumference of abdomen, and BMI of all the patients were decreased, and the decrease was more significantly in the treatment group than in the control group (P<0.05).       Conclusion       Exenatide combined with metformin effectively improves the C-peptide level, and reduces blood glucose, HbA1c, body weight, circumference of abdomen and BMI in the patients with type 2 diabetes.

相似文献/References:

[1]胡小春,刘浩宇,覃数,等.Exendin-4对人脐静脉内皮细胞内质网应激损伤的拮抗作用[J].陆军军医大学学报(原第三军医大学学报),2013,35(17):1827.
 Hu Xiaochun,Liu Haoyu,Qin Shu,et al.Effect of exendin-4 on human umbilical vein endothelial cells with endoplasmic reticulum stress[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(15):1827.
[2]张先祥,阳皓,杨刚毅,等.艾塞那肽与沙格列汀联合二甲双胍治疗2型糖尿病患者的疗效与安全性比较[J].陆军军医大学学报(原第三军医大学学报),2013,35(14):1531.
 Zhang Xianxiang,Yang Hao,Yang Gangyi,et al.Efficacy and safety of exenatide versus saxagliptin combined with metformin in patients with type 2 diabetes mellitus[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(15):1531.

更新日期/Last Update: 2014-07-25